Skip to content
Ontario Rheumatology Association
  • Login
  • Login
  • About
    • Overview
    • Organizational Priorities and Committees
    • Leadership
    • Annual Awards
  • Events
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • RheumView
    • Rheumatology EMR Database at ICES
  • Members
    • Overview
    • Member Directory
    • Peer Mentor Forum
    • Resource for Members
    • Become A Member
    • Renew Membership
    • Membership Perks
  • News
    • Overview
    • Drug Shortages Info
    • Newsletters
    • Other Publications
    • Info Hub
  • Contact
  • Directory
  • Login
  • About
    • Overview
    • Organizational Priorities and Committees
    • Leadership
    • Annual Awards
  • Events
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • RheumView
    • Rheumatology EMR Database at ICES
  • Members
    • Overview
    • Member Directory
    • Peer Mentor Forum
    • Resource for Members
    • Become A Member
    • Renew Membership
    • Membership Perks
  • News
    • Overview
    • Drug Shortages Info
    • Newsletters
    • Other Publications
    • Info Hub
  • Contact
  • Directory

Government Affairs Committee

Jane Purvis • Edition: Fall 2021

Jane PurvisGovernment Affairs Committee report

The Government Affairs Committee has been very busy over the last several months.  After a lot of intense work between the ORA and the OMA, we have been able to get the government to agree to allow for patient attestation with a list of their medications are order to access third vaccine doses rather than a form being required.  As well the government has issued an explicit list of which medications will be included so that we are now clear on who qualifies for a third dose amongst our patients.

We continue to work with the government on lab test reform, to try and have over utilize tests ordered less frequently, and to get coverage for some of are important but as yet unfunded tests such as anti-CCP antibodies and ANCA.  We are also continuing to work with the government on biosimilars though no announcement has been made on that subject as of yet.

The Government Affairs Committee has created an opportunity for its members and other committee chairs to learn about advocacy and the government, through courses with Ryan Clarke.  We anticipate that this four-part series will be very beneficial going forwards, allowing committee members greater impact in their roles.

We have another meeting with the Ministry of Health EAP department scheduled in October.  We plan to discuss medications for interstitial lung disease and connective tissue disease related fingertip ulceration, and biosimilars, particularly around the effectiveness of the newer patient support programs.  We are also going to discuss the coverage of colchicine and we are looking for an update on JAK inhibitor indications and restrictions.

As always, if you have questions related to issues that pertain to government or medications do not hesitate to contact us at admin@ontariorheum.ca

 

 

 

Other Articles in the Fall 2021 Newsletter

  • President's Message
  • OMA Section on Rheumatology Report
  • Northern Ontario Committee
  • Geoff Carr Fellowship 2022/2023 - Applications Now Being Accepted
  • ORADE Report: Dr. Nathaniel Dostrovsky
  • 2022 ORA Membership Renewals Begin November 1!
  • News from Ottawa & Northern Ontario: Recent Moves & Retirements
  • Informatics Committee Update
Editions
  • Winter 2021
  • Fall 2020
  • Summer 2020
  • Winter 2020
  • Winter 2019
  • Fall 2019
  • Spring 2019
  • Winter 2018
  • Fall 2018
  • Summer 2018
  • Summer 2017
  • Spring 2017
  • Fall 2017
  • Archive
  • Meet the Speakers: ORA 20th Annual Scientific Meeting
Committees
Communications Informatics Models of Care OMA
Tags
Biosimilar CSDTH Models of Care OBRI OMA pCPA SADIE

Contributors

The ORA’s executive members are the core contributors to the newsletter. The ORA welcomes guest contributions to the newsletter from members-at-large and others in the rheumatology community.

Contributors
Ontario Rheumatology Association

© 2020 Ontario Rheumatology Association. All Rights Reserved. Website by Digital Chaos Inc.

  • About
  • Annual Awards
  • Events
  • EAP & Limited Use Codes
  • Exceptional Access Program
  • EAP Forms and Downloads
  • Limited Use Codes
  • Biosimilar Fact Sheet
  • NIHB Drug List
  • MOHLTC IVIG Request Form
  • Informatics
  • Members
  • Member Directory
  • Past Meeting Resources
  • Peer Mentor Forum
  • BecomeA Member
  • Renew Membership
  • News
  • Newsletters
  • Drug Shortages Info
  • Other Publications
  • Info Hub
  • Contact
  • Privacy